Publications & Posters
Scholarly publications
Immuno-Oncology
SRK-181
June 2024
American Society of Clinical Oncology
Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase
Spinal Muscular Atrophy
Apitegromab
March 2024
4th Scientific International Congress on SMA
Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2-21 Years with Spinal Muscular Atrophy
Spinal Muscular Atrophy
March 2024
2024 Muscular Dystrophy Association Clinical and Scientific Conference
Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review
Spinal Muscular Atrophy
Apitegromab
March 2024
2024 Muscular Dystrophy Association Clinical and Scientific Conference
Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2-21 years with spinal muscular atrophy
Spinal Muscular Atrophy
Apitegromab
February 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Cardiometabolic Disease
SRK-439
February 2024
Keystone Symposia: Obesity Causes and Consequences Conference
